stoxline Quote Chart Rank Option Currency Glossary
Emergent BioSolutions Inc. (EBS)
11.42  -0.01 (-0.09%)    07-19 14:16
Open: 11.21
High: 11.97
Volume: 1,680,831
Pre. Close: 11.43
Low: 11.04
Market Cap: 598(M)
Technical analysis
2024-07-19 1:49:57 PM
Short term     
Mid term     
Targets 6-month :  14.88 1-year :  17.38
Resists First :  12.73 Second :  14.88
Pivot price 9.46
Supports First :  8.42 Second :  5.75
MAs MA(5) :  11.69 MA(20) :  8.78
MA(100) :  4.69 MA(250) :  3.75
MACD MACD :  1.5 Signal :  1.2
%K %D K(14,3) :  83.1 D(3) :  87.8
RSI RSI(14): 79.2
52-week High :  12.73 Low :  1.41
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ EBS ] has closed below upper band by 21.6%. Bollinger Bands are 231.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 12.26 - 12.33 12.33 - 12.39
Low: 10.91 - 10.99 10.99 - 11.05
Close: 11.31 - 11.43 11.43 - 11.53
Company Description

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Headline News

Fri, 19 Jul 2024
Emergent BioSolutions (NYSE:EBS) Reaches New 12-Month High at $12.74 - Defense World

Thu, 18 Jul 2024
Emergent BioSolutions (NYSE:EBS) Stock Price Down 3% - MarketBeat

Mon, 15 Jul 2024
Emergent BioSolutions: A Much-Needed Mid-Stage Turnaround In Process (NYSE:EBS) - Seeking Alpha

Sun, 14 Jul 2024
Short Interest in Emergent BioSolutions Inc. (NYSE:EBS) Drops By 18.0% - MarketBeat

Sat, 13 Jul 2024
Emergent BioSolutions (NYSE:EBS) Sets New 52-Week High at $9.74 - American Banking and Market News

Fri, 12 Jul 2024
Emergent BioSolutions grants stock award to EVP -

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 52 (M)
Shares Float 51 (M)
Held by Insiders 2.1 (%)
Held by Institutions 69.8 (%)
Shares Short 6,330 (K)
Shares Short P.Month 6,040 (K)
Stock Financials
EPS -10.98
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 12.67
Profit Margin -47.7 %
Operating Margin 13.2 %
Return on Assets (ttm) -0.4 %
Return on Equity (ttm) -60.6 %
Qtrly Rev. Growth 82.8 %
Gross Profit (p.s.) 0
Sales Per Share 22.7
EBITDA (p.s.) 1.91
Qtrly Earnings Growth 0 %
Operating Cash Flow -85 (M)
Levered Free Cash Flow 134 (M)
Stock Valuations
PE Ratio -1.06
PEG Ratio 0.2
Price to Book value 0.91
Price to Sales 0.5
Price to Cash Flow -7.15
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android